中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 1
Jan.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(1): 14-20

Treatment strategies for chronic hepatitis B based on covalently closed circular DNA dynamics

DOI: 10.12449/JCH260103

  • Key Laboratory of Molecular Biology of Infectious Diseases Designated by the Chinese Ministry of Education，Chongqing Medical University，Chongqing 400016，China

Research funding:

National Key R&D Program of China (2022YFA1303600);

Key Project of National Natural Science Foundation of China (82530076);

General Project of National Natural Science Foundation of China (82470634)

More Information
  • Corresponding author: HUANG Ailong， ahuang1964@163.com （ORCID： 0000-0003-2225-9550）
  • Received Date: 2025-11-03
  • Accepted Date: 2025-11-30
  • Published Date: 2026-01-25
    Abstract
  • Cure of chronic hepatitis B virus （HBV） infection is the ultimate goal in HBV-related research， and exploring potential curative pathways may help to identify key research directions. Covalently closed circular DNA （cccDNA）， as the most difficult genetic material to be eliminated within the HBV replication cycle， is not only a primary impediment to achieving cure， but also a key issue for establishing an analytical framework for cure strategies. This article reviews the thinking framework of “cccDNA dynamics”， further elaborates on its core implications， and systematically discusses the main strategies to promote cccDNA decay.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    LINK JO, TAYLOR JG, XU LH, et al. Discovery of ledipasvir(GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection[J]. J Med Chem, 2014, 57( 5): 2033- 2046. DOI: 10.1021/jm401499g.
    [2]
    CHATTERJEE A, SMITH PF, PERELSON AS. Hepatitis C viral kinetics: The past, present, and future[J]. Clin Liver Dis, 2013, 17( 1): 13- 26. DOI: 10.1016/j.cld.2012.09.003.
    [3]
    NGUYEN THT, GUEDJ J, UPRICHARD SL, et al. The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: Can we still rely on viral kinetics?[J]. Sci Rep, 2017, 7( 1): 10233. DOI: 10.1038/s41598-017-09776-z.
    [4]
    NOWAK MA, BONHOEFFER S, HILL AM, et al. Viral dynamics in hepatitis B virus infection[J]. Proc Natl Acad Sci USA, 1996, 93( 9): 4398- 4402. DOI: 10.1073/pnas.93.9.4398.
    [5]
    IMAM H, KHAN M, GOKHALE NS, et al. N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle[J]. Proc Natl Acad Sci USA, 2018, 115( 35): 8829- 8834. DOI: 10.1073/pnas.1808319115.
    [6]
    LIU F, LEE ACH, GUO F, et al. Host poly(A) polymerases PAPD5 and PAPD7 provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA[J]. J Virol, 2021, 95( 18): e00574-21. DOI: 10.1128/JVI.00574-21.
    [7]
    TABATA K, NEUFELDT CJ, BARTENSCHLAGER R. Hepatitis C virus replication[J]. Cold Spring Harb Perspect Med, 2020, 10( 3): a037093. DOI: 10.1101/cshperspect.a037093.
    [8]
    MATA M, NEBEN S, MAJZOUB K, et al. Impact of a patient-derived hepatitis C viral RNA genome with a mutated microRNA binding site[J]. PLoS Pathog, 2019, 15( 5): e1007467. DOI: 10.1371/journal.ppat.1007467.
    [9]
    HU JL, HUANG AL. A conceptual framework for dynamics of cccDNA in hepatitis B virus[J]. Chin J Hepatol, 2023, 31( 5): 545- 550. DOI: 10.3760/cma.j.cn501113-20230330-00134.

    胡接力, 黄爱龙. 乙型肝炎病毒cccDNA动力学的思维框架[J]. 中华肝脏病杂志, 2023, 31( 5): 545- 550. DOI: 10.3760/cma.j.cn501113-20230330-00134.
    [11]
    HU JL, HUANG AL. Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics[J]. Virol Sin, 2024, 39( 1): 9- 23. DOI: 10.1016/j.virs.2023.12.005.
    [12]
    ASABE S, WIELAND SF, CHATTOPADHYAY PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection[J]. J Virol, 2009, 83( 19): 9652- 9662. DOI: 10.1128/JVI.00867-09.
    [13]
    GUIDOTTI LG, ROCHFORD R, CHUNG J, et al. Viral clearance without destruction of infected cells during acute HBV infection[J]. Science, 1999, 284( 5415): 825- 829. DOI: 10.1126/science.284.5415.825.
    [14]
    HU JL, HUANG AL. Chronic infection of hepatitis B virus and cellular immunity[J]. Chin J Microbiol Immunol, 2023, 43( 7): 494- 501. DOI: 10.3760/cma.j.cn112309-20230619-00179.

    胡接力, 黄爱龙. 慢性乙型肝炎病毒感染与细胞免疫[J]. 中华微生物学和免疫学杂志, 2023, 43( 7): 494- 501. DOI: 10.3760/cma.j.cn112309-20230619-00179.
    [15]
    FRELIN L, WAHLSTRÖM T, TUCKER AE, et al. A mechanism to explain the selection of the hepatitis E antigen-negative mutant during chronic hepatitis B virus infection[J]. J Virol, 2009, 83( 3): 1379- 1392. DOI: 10.1128/JVI.01902-08.
    [16]
    VOLZ T, LUTGEHETMANN M, WACHTLER P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients[J]. Gastroenterology, 2007, 133( 3): 843- 852. DOI: 10.1053/j.gastro.2007.06.057.
    [17]
    WALKER A, SCHWARZ T, BRINKMANN-PAULUKAT J, et al. Immune escape pathways from the HBV core(18-27) CD8 T cell response are driven by individual HLA class I alleles[J]. Front Immunol, 2022, 13: 1045498. DOI: 10.3389/fimmu.2022.1045498.
    [18]
    LI GX, YANG DL, LIU X, et al. Precore mutation enhances viral replication to facilitate persistent infection especially in HBeAg-negative patients[J]. Virol Sin, 2024, 39( 2): 319- 330. DOI: 10.1016/j.virs.2024.03.003.
    [19]
    UCHIDA T, IMAMURA M, HAYES CN, et al. HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice[J]. Hepatology, 2023, 78( 3): 929- 942. DOI: 10.1097/HEP.0000000000000335.
    [20]
    ROSSI M, VECCHI A, TIEZZI C, et al. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro[J]. Gut, 2023, 72( 11): 2123- 2137. DOI: 10.1136/gutjnl-2022-327202.
    [21]
    HOOGEVEEN RC, ROBIDOUX MP, SCHWARZ T, et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection[J]. Gut, 2019, 68( 5): 893- 904. DOI: 10.1136/gutjnl-2018-316644.
    [22]
    BAULU E, GARDET C, CHUVIN N, et al. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives[J]. Sci Adv, 2023, 9( 7): eadf3700. DOI: 10.1126/sciadv.adf3700.
    [23]
    HU JL, JI YW, PENG P, et al. Clinical cure and safe drug withdrawal in chronic hepatitis B[J]. Chin J Hepatol, 2025, 33( 6): 526- 533. DOI: 10.3760/cma.j.cn501113-20250106-00008.

    胡接力, 季业伟, 彭湃, 等. 慢性乙型肝炎临床治愈与安全停药[J]. 中华肝脏病杂志, 2025, 33( 6): 526- 533. DOI: 10.3760/cma.j.cn501113-20250106-00008.
    [24]
    WU XA, QUAN DM, LI W, et al. Clinical results of an HBV-specific T-cell receptor-T-cell therapy(SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial[J]. Gut, 2025, 75( 1): 147- 160. DOI: 10.1136/gutjnl-2025-335456.
    [25]
    WAN XS, WISSKIRCHEN K, JIN T, et al. Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting[J]. Clin Mol Hepatol, 2024, 30( 4): 735- 755. DOI: 10.3350/cmh.2024.0058.
    [26]
    JIN X, LI L. New advances in tree shrew model in experimental studies of hepatitis B virus[J]. J Clin Hepatol, 2015, 31( 9): 1524- 1527. DOI: 10.3969/j.issn.1001-5256.2015.09.041.

    金雄, 李立. 乙型肝炎树鼩模型的研究进展[J]. 临床肝胆病杂志, 2015, 31( 9): 1524- 1527. DOI: 10.3969/j.issn.1001-5256.2015.09.041.
    [27]
    WALTER E, KEIST R, NIEDERÖST B, et al. Hepatitis B virus infection of Tupaia hepatocytes in vitro and in vivo[J]. Hepatology, 1996, 24( 1): 1- 5. DOI: 10.1002/hep.510240101.
    [28]
    YUEN MF, HEO J, KUMADA H, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy[J]. J Hepatol, 2022, 77( 4): 967- 977. DOI: 10.1016/j.jhep.2022.05.031.
    [29]
    JOSHI S, FREUDENBERG JM, SINGH JM, et al. Immunomodulation by bepirovirsen may induce killing of infected hepatocytes(B-Together study)[J]. Hepatol Int, 2025. DOI: 10.1007/s12072-025-10917-0.[ Epub ahead of print]
    [30]
    YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387( 21): 1957- 1968. DOI: 10.1056/NEJMoa2210027.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (133) PDF downloads(52) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return